康基醫療(09997.HK)附屬向精鋒醫療投資8,000萬元人幣
康基醫療(09997.HK)公布,全資附屬公司康基香港等投資者與精鋒醫療訂立投資協議,康基香港同意於其B輪融資投資8,000萬元人民幣,以認購精鋒醫療經擴大註冊股本約2.03%。
該輪融資的其他投資者包括由控股股東全資擁有的有限合夥企業銀凱欣及由公司現有股東的母集團LYFE Capital全資擁有的公司Guadalupe Peak。
公司指,建議投資提供集團洞察手術機器人行業技術發展、臨床應用及反饋以及監管環境最新趨勢的機會。其為集團於智能手術設備及器械行業以及參與中國手術機器人行業發展的戰略投資中不可或缺的一環。另外,亦為公司與精鋒醫療間更廣泛及更深入的潛在合作關係奠定基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.